Medication for Self-Injurious Head-Banging in a 9-Year-Old with Autism
Risperidone is the recommended first-line medication for treating self-injurious head-banging behavior in a 9-year-old child with autism, with a typical starting dose of 0.5 mg/day, titrated up to 0.5-3.5 mg/day based on response and tolerability. 1, 2
Primary Recommendation: Atypical Antipsychotics
Risperidone (First-Line Choice)
Risperidone has the strongest evidence base for treating self-injurious behavior in children with autism and is FDA-approved for irritability associated with autism spectrum disorder. 1
Efficacy for self-injury: Risperidone demonstrated a large effect in reducing self-injury (SMD -1.43) in controlled trials, with 69% of children showing positive response compared to 12% on placebo 2, 3
Dosing for this age group: Start at 0.5 mg/day and titrate to 0.5-3.5 mg/day over several weeks, with most children responding to doses around 1-2 mg/day 1, 2
Timeline for response: Significant improvement in self-injurious behavior typically occurs within 8 weeks, with benefits maintained at 6 months in two-thirds of responders 2, 4
Specific evidence for head-banging: Head-hitting was identified as the most frequent form of self-aggression in autism, and risperidone showed reduction in frequency of these behaviors 5, 6
Important Side Effects to Monitor
Weight gain is the most significant concern with risperidone, with average increases of 2.7 kg over 8 weeks and 5.1 kg over 6 months 2, 4
Monitor for increased appetite, fatigue, drowsiness, dizziness, and drooling, which occur more frequently than placebo 2, 3
Metabolic monitoring is essential: obtain baseline weight, BMI, fasting glucose, and lipid panel, then monitor regularly 1
Extrapyramidal symptoms can occur but are generally less common than with older antipsychotics 1
Aripiprazole (Alternative First-Line Option)
Aripiprazole is another FDA-approved option for irritability in autism and may have a more favorable metabolic profile than risperidone. 1, 7
Dosing: 5-15 mg/day, with 56% positive response rate versus 35% on placebo 1, 7
May cause less weight gain than risperidone (approximately 30% experience clinically relevant weight gain) 7
Side effects include somnolence, drooling, tremor, fatigue, and vomiting 1
Second-Line Options
Naltrexone
Naltrexone showed a positive trend for self-injurious behavior reduction in children aged 3-8 years at doses of 0.5-1 mg/kg/day 1, 8
One study (Campbell et al., 1990) demonstrated significantly decreased hyperactivity with positive trend for self-injurious behavior, with no significant side effects 1
However, long-term data are lacking in the autism population 8
May be considered when atypical antipsychotics are not tolerated or contraindicated 8
Emerging Option: Gabapentin
A recent 2025 case report suggests gabapentin may be effective for severe self-injurious behaviors, particularly when chronic pain is suspected as a contributing factor. 9
Dosing: Titrated up to 600 mg three times daily in the reported case 9
Notable reduction in frequency and severity of self-injurious behaviors within days 9
Generally well-tolerated with mild adverse effects like fatigue and dizziness 9
This represents very preliminary evidence and requires further research before routine recommendation 9
Critical Clinical Considerations
Behavioral Interventions Must Be Concurrent
Combining medication with parent training is moderately more efficacious than medication alone for decreasing serious behavioral disturbances. 1
Pharmacotherapy should target the specific symptom of self-injury while educational and behavioral interventions continue 1
The goal is to facilitate the child's adjustment and engagement with educational intervention, not just symptom suppression 1
Assessment of Contributing Factors
Before initiating medication, evaluate for underlying causes of head-banging: 1
Rule out medical conditions causing pain (dental problems, ear infections, headaches) that may trigger self-injury 9
Assess severity of autism, as this is the strongest predictor of self-injurious behaviors 6
Evaluate for sensory processing abnormalities and intellectual disability, both significantly associated with self-injurious behaviors 6
Monitoring Treatment Response
Use objective rating scales to monitor response: 1, 2
The Aberrant Behavior Checklist (ABC) Irritability subscale is the standard outcome measure 2, 4
Clinical Global Impressions-Improvement (CGI-I) scale provides global assessment 2
A positive response is defined as ≥25% decrease in ABC Irritability score plus "much improved" or "very much improved" on CGI-I 1
Common Pitfalls to Avoid
Do not use antidepressants as first-line: There is no clear evidence that antidepressants reduce irritability or self-injury in autism 3
Do not rely on ADHD medications alone: While methylphenidate and other ADHD medications may reduce irritability slightly, evidence for self-injury reduction is lacking 1, 3
Do not discontinue prematurely: Discontinuation of risperidone after 6 months was associated with 62.5% relapse rate versus 12.5% with continued treatment 4
Do not ignore the need for long-term monitoring: While short-term efficacy is established, long-term effects of antipsychotic therapy in pediatric populations require ongoing surveillance for metabolic complications and tardive dyskinesia 2, 7